Sarcoidosis natural history, complications and prognosis

Revision as of 20:52, 10 May 2018 by Roshan (talk | contribs)
Jump to navigation Jump to search

Sarcoidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Sarcoidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Sarcoidosis natural history, complications and prognosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Sarcoidosis natural history, complications and prognosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Sarcoidosis natural history, complications and prognosis

CDC on Sarcoidosis natural history, complications and prognosis

Sarcoidosis natural history, complications and prognosis in the news

Blogs on Sarcoidosis natural history, complications and prognosis

Directions to Hospitals Treating Sarcoidosis

Risk calculators and risk factors for Sarcoidosis natural history, complications and prognosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Roshan Dinparasti Saleh M.D.

Overview

Please help WikiDoc by adding content here. It's easy! Click here to learn about editing.

Natural History

The overall mortality in sarcoidosis is low (about 5%), and many patients with spontaneous regression will never require treatment[1]. In people who need treatment, important differences exist between African-American and white patients. African-American patients with sarcoidosis experience a more severe and systemic disease and 12 times higher mortality [2]

Complications

Prognosis

  • African-American patients with sarcoidosis experience a more severe and systemic disease and 12 times higher mortality [2]


References

  1. Gerke AK: Morbidity and mortality in sarcoidosis. Curr Opin Pulm Med 20:472–478, 2014.
  2. 2.0 2.1 Mirsaeidi M, et al: Racial difference in sarcoidosis mortality in the United States. Chest 147:438–449, 2015.
  3. Fisher KA, Serlin DM, Wilson KC, et al: Sarcoidosis-associated pulmonary hypertension: outcome with long term epoprostenol treatment. Chest 130(5):1481–1488, 2006.
  4. Preston IR, Klinger JR, Landzberg MJ, et al: Vasoresponsiveness of sarcoidosis-associated pulmonary hypertension. Chest 120(3):866–872, 2001.
  5. de Kleijn WP, de Vries J, Lower EE, et al: Fatigue in sarcoidosis: a systematic review. Curr Opin Pulm Med 15(5):499–506, 2009.
  6. Kavathia D, Buckley JD, Rao D, et al: Elevated 1, 25-dihydroxyvitamin D levels are associated with protracted treatment in sarcoidosis. Respir Med 104(4):564–570, 2010.
  7. Gonnelli S, Rottoli P, Cepollaro C, et al: Prevention of corticosteroidinduced osteoporosis with alendronate in sarcoid patients. Calcif Tissue Int 61(5):382–385, 1997.
  8. Denning DW, Pleuvry A, Cole DC: Global burden of chronic pulmonary aspergillosis complicating sarcoidosis. Eur Respir J 41(3):621–626, 2013.
  9. Pena TA, Soubani AO, Samavati L: Aspergillus lung disease in patients with sarcoidosis: a case series and review of the literature. Lung 189(2):167–172, 2011.
  10. Baughman RP, Lower EE: Fungal infections as a complication of therapy for sarcoidosis. QJM 98:451–456, 2005.

Template:WH Template:WS